Bahnhofstrasse 7
Zug 6300
Switzerland
41 41 711 9325
https://oculis.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 36
Nombre | Título | Paga | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Dr. Riad Sherif M.B.A., M.D. | CEO & Director | N/A | N/A | 1968 |
Ms. Sylvia Cheung | Chief Financial Officer | N/A | N/A | 1975 |
Dr. Ramin Tadayoni M.D., Ph.D. | Chief Scientific Officer | N/A | N/A | N/A |
Ms. Virginia R. Dean | Chief Human Resources Officer | N/A | N/A | 1967 |
Dr. Bastian Dehmel M.D. | Chief Development Officer | N/A | N/A | 1971 |
Mr. Páll Ragnar Jóhannesson | Chief Business Officer | N/A | N/A | 1982 |
Ms. Rebecca Weil | Chief Commercial Officer | N/A | N/A | N/A |
Dr. Snehal Shah Pharm.D. | President of Research & Development | N/A | N/A | N/A |
Dr. Sharon Klier M.D., M.P.H. | Chief Development Officer | N/A | N/A | N/A |
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.
El ISS Governance QualityScore de Oculis Holding AG, a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.